Dishman is a contract research and manufacturing services company specialising in developing and manufacturing active pharmaceutical ingredients for its customers. On Monday, Tesaro Inc, an oncology focussed biopharmaceutical company, announced that the US drug regulator has approved "Zejula" to treat women with recurrent ovarian cancer. The news sent shares of Dishman rising Rs 46.35, or 19.99 per cent, at Rs 278.20. In a clarification sent to the stock exchanges, Dishman said that it currently has around thirteen molecules in late phase III development across various customers. US drug regulator on companies not meeting manufacturing norms.

Source: The Telegraph March 28, 2017 19:42 UTC